Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis.
- 1 October 1988
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 6 (10) , 1621-1624
- https://doi.org/10.1200/jco.1988.6.10.1621
Abstract
We analyzed a retrospective series of 195 patients with documented intracerebral metastases (ICM) to assess the frequency of late seizure development and the impact of prophylactic anticonvulsants. Eighteen percent of the patients presented with seizures. Of the remaining patients, 40% received prophylactic anticonvulsants (diphenylhydantoin [DPH] in greater than 90%). Ten percent developed late seizures at an interval from the diagnosis of ICM ranging from 1 to 59 weeks. No patient with a posterior fossa lesion developed seizure; conversely, patients with evidence on initial examination of cerebral hemispheric dysfunction had a higher incidence of late seizure development. The incidence of seizure was virtually identical in patients who received DPH compared with those in whom it was withheld, although two thirds of patients who developed seizure while on DPH had a serum anticonvulsant level that was subtherapeutic. Based on the above findings and until prospective data become available, we recommend that anticonvulsants be withheld in newly-diagnosed patients with ICM until the first seizure.This publication has 4 references indexed in Scilit:
- Erythema multiforme and Stevens‐Johnson syndrome in patients receiving cranial irradiation and phenytoinNeurology, 1988
- Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients.Journal of Neurology, Neurosurgery & Psychiatry, 1984
- Effects of phenytoin on man's immunityThe American Journal of Medicine, 1983
- Intracerebral metastases in solid-tumor patients: Natural history and results of treatmentCancer, 1981